Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Chief Financial Officer | February 14, 2022 | February 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date February 14, 2022 · Filed February 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2032-02-13 | Direct | 54,006 |
Reported balance
After 2022-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-14 · Grant · Acquired 54,006 · Balance 54,006 F1: This option represents a right to purchase a total of 54,006 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 17,322 |
Reported balance
After 2022-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-14 · Grant · Acquired 17,322 · Balance 17,322 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 54,006 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2022 Filed Feb 17, 2022 02:32 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 17,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-005831 · form4.xml · derivative · entry 2 Garcia-Parada Carlos · CIK 0001839342 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,322 Underlying: Common Stock · 17,322 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:32 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 54,006 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001140361-22-005831 · form4.xml · derivative · entry 1 Garcia-Parada Carlos · CIK 0001839342 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,006 Underlying: Common Stock · 54,006 shares Expires 2032-02-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 54,006 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $35.60 | $0.00 |
DisclosureSEC source: 0001140361-21-031349 · form4.xml · derivative · entry 1 Garcia-Parada Carlos · CIK 0001839342 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-09-13 F1 · derivative.exercise_date: The option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on September 13, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:21 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $56.49 | $0.00 |
DisclosureSEC source: 0001140361-21-000393 · form4.xml · derivative · entry 1 Garcia-Parada Carlos · CIK 0001839342 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The option represents a right to purchase a total of 125,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on January 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.